These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25006726)

  • 1. Spironolactone for heart failure with preserved ejection fraction.
    Pfeffer MA; Pitt B; McKinlay SM
    N Engl J Med; 2014 Jul; 371(2):181-2. PubMed ID: 25006726
    [No Abstract]   [Full Text] [Related]  

  • 2. Spironolactone for heart failure with preserved ejection fraction.
    Morawietz H; Bornstein SR
    N Engl J Med; 2014 Jul; 371(2):181. PubMed ID: 25006730
    [No Abstract]   [Full Text] [Related]  

  • 3. Spironolactone for heart failure with preserved ejection fraction.
    Kumar N; Garg N
    N Engl J Med; 2014 Jul; 371(2):180. PubMed ID: 25006729
    [No Abstract]   [Full Text] [Related]  

  • 4. Spironolactone for heart failure with preserved ejection fraction.
    Efthimiadis GK; Zegkos T; Karvounis H
    N Engl J Med; 2014 Jul; 371(2):179-80. PubMed ID: 25006728
    [No Abstract]   [Full Text] [Related]  

  • 5. Spironolactone for heart failure with preserved ejection fraction.
    Dalzell JR
    N Engl J Med; 2014 Jul; 371(2):179. PubMed ID: 25006727
    [No Abstract]   [Full Text] [Related]  

  • 6. Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction.
    Kelly J; Granger CB
    Ann Intern Med; 2014 Oct; 161(8):JC6. PubMed ID: 25329223
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
    Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Mineralocorticoid Receptor Antagonists in Individuals With Heart Failure With Preserved Ejection Fraction: A Systematic Review.
    Fernandes BP; Conceição LSR; Martins-Filho PRS; de Santana Motta DRM; Carvalho VO
    J Card Fail; 2018 Sep; 24(9):618-621. PubMed ID: 30194985
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical Question: In congestive heart failure patients with preserved ejection fraction, does spironolactone improve cardiac outcomes?
    Onarecker C
    J Okla State Med Assoc; 2016 Sep; 109(9):437-8. PubMed ID: 29261854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
    Mitter SS; Shah SJ
    Curr Atheroscler Rep; 2015 Nov; 17(11):64. PubMed ID: 26408016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
    Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
    Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of the H
    Myhre PL; Vaduganathan M; Claggett BL; Lam CSP; Desai AS; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Shah AM; Lewis EF; Rouleau J; Pitt B; Solomon SD
    Eur J Heart Fail; 2019 Oct; 21(10):1288-1291. PubMed ID: 31332920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.
    Patel RB; Shah SJ; Fonarow GC; Butler J; Vaduganathan M
    Curr Heart Fail Rep; 2017 Aug; 14(4):217-222. PubMed ID: 28647918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone: diuretic or disease-modifying drug in heart failure with preserved ejection fraction?
    Verbrugge FH; Damman K
    Eur J Heart Fail; 2020 Sep; 22(9):1611-1614. PubMed ID: 32812323
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic implications of overt congestion in heart failure with preserved ejection fraction and the interaction with spironolactone: Insights from TOPCAT.
    Lin Y; Zhao H; Hu D; Huang J; Peng Y; Li J; Xu D; Zeng Q
    Chin Med J (Engl); 2024 May; 137(10):1249-1251. PubMed ID: 37815321
    [No Abstract]   [Full Text] [Related]  

  • 17. Spironolactone, fibrosis and heart failure with preserved ejection fraction.
    Reddy YNV; Sundaram V
    Eur J Heart Fail; 2022 Sep; 24(9):1569-1572. PubMed ID: 35851716
    [No Abstract]   [Full Text] [Related]  

  • 18. Spironolactone an important addition to heart-failure treatment, study shows.
    Miller JL
    Am J Health Syst Pharm; 1999 Sep; 56(17):1695. PubMed ID: 10512491
    [No Abstract]   [Full Text] [Related]  

  • 19. Spironolactone in patients with heart failure.
    Glick G
    N Engl J Med; 2000 Jan; 342(2):133; author reply 133-4. PubMed ID: 10636752
    [No Abstract]   [Full Text] [Related]  

  • 20. Body fat phenotypes and treatment response to spironolactone in ambulatory patients with heart failure and preserved ejection fraction: a post-hoc analysis of the Aldo-DHF trial.
    Petutschnigg J; Ferreira JP; Holzendorf V; Trippel TD; Hashemi D; Wachter R; Herrmann-Lingen C; Hasenfuß G; Zannad F; Pieske B; Edelmann F
    Eur J Heart Fail; 2020 Mar; 22(3):559-561. PubMed ID: 31912594
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.